Emerging evidence suggests that dysregulation of these novel acylations strongly correlates with numerous diseases, including cancer, neurological disorders, metabolic diseases, etc. Some inhibitors targeting novel acylation modifications have been used clinically, yielding promising results; e.g., inhibitors targeting acyltransferases p300 and CREB-binding protein (p300/CBP) have been under clinical evaluation in patients with hematologic malignancies or advanced and drug-resistant solid tumors [7]. Here, EP300 is linked to metabolic disease.